Boston Scientific (BSX) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, BSX crossed above the 20-day moving average, suggesting a short-term bullish trend.
BSX, JNJ and GEHC are leveraging AI to boost device performance, diagnostics and surgical precision in 2025.
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
BSX rides on strong MedSurg growth and strategic acquisitions amid currency headwinds.
In the most recent trading session, Boston Scientific (BSX) closed at $102.41, indicating a -1.37% shift from the previous trading day.
Boston Scientific (BSX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
BSX rallies 40.5% in a year, fueled by WATCHMAN growth, MedSurg gains, acquisitions and global expansion efforts.
Boston Scientific (BSX) reached $106.53 at the closing of the latest trading day, reflecting a +1.86% change compared to its last close.
Investors are increasingly eyeing the fast-growing MedSurg equipment space, which is projected to witness a compound annual growth rate (CAGR) of 9.54% from 2025 to 2030 (per Grand View Research). Two prominent companies with a strong foothold in this space are Boston Scientific BSX and Medtronic MDT.
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Boston Scientific lifts its 2025 sales and EPS outlook after a strong Q1, with cardiology and EP segments fueling major gains.